Who are Bevacizumab and trastuzumab maintenance therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LONCASTUXIMAB TESIRINE, Tivdak, Tisotumab Vedotin, Besponsa, Kadcyla, Mylotarg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bevacizumab-and-trastuzumab-maintenance-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Bevacizumab and trastuzumab maintenance therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab and trastuzumab maintenance therapy (Bevacizumab and trastuzumab maintenance therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibody-drug conjugate. Area: Oncology.

phase 2 Antibody-drug conjugate VEGFA, HER2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bevacizumab and trastuzumab maintenance therapy (Bevacizumab and trastuzumab maintenance therapy) — Sanofi. Inhibits vascular endothelial growth factor A (VEGFA) and human epidermal growth factor receptor 2 (HER2)

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bevacizumab and trastuzumab maintenance therapy TARGET	Bevacizumab and trastuzumab maintenance therapy	Sanofi	phase 2	Antibody-drug conjugate	VEGFA, HER2
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Tivdak	tisotumab-vedotin	SEAGEN	marketed	Antibody-drug conjugate	Tissue factor	2021-01-01
Tisotumab Vedotin	tivdak	SEAGEN	marketed	Antibody-Drug Conjugate (ADC)	Tissue factor	2021-01-01
Besponsa	inotuzumab-ozogamicin	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD22	2017-01-01
Kadcyla	trastuzumab-emtansine	Roche	marketed	Antibody-drug conjugate	Receptor tyrosine-protein kinase erbB-2	2013-01-01
Mylotarg	Gemtuzumab Ozogamicin	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD33 antigen	2000-01-01

Recent regulatory actions (last 90 days)

2026-03-26 — Kadcyla · FDA · approved · US · Roche
2026-02-20 — LONCASTUXIMAB TESIRINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibody-drug conjugate class)

Amgen · 1 drug in this class
Hellenic Cooperative Oncology Group · 1 drug in this class
Roche · 1 drug in this class
SEAGEN · 1 drug in this class
Sanofi · 1 drug in this class
Sung-Soo Park · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bevacizumab and trastuzumab maintenance therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-and-trastuzumab-maintenance-therapy. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab